Why Farbe Firma is the Top Manufacturer of Tenoxicam for Injection
- Maulik Sudani
- 4 hours ago
- 6 min read
Last Updated: May 29, 2026
TL;DR: Tenoxicam for Injection — a sterile freeze-dried (lyophilised) parenteral powder of the oxicam-class non-steroidal anti-inflammatory drug (NSAID) tenoxicam, supplied as 20 mg per vial reconstituted in 2 mL water for injection — is the long-acting, once-daily injectable NSAID of choice for short-term management of post-operative pain, acute musculoskeletal trauma, acute exacerbations of rheumatoid arthritis, ankylosing spondylitis and osteoarthritis, and acute gouty arthritis where rapid systemic anti-inflammatory action is needed. With its long elimination half-life of ~72 hours, a single 20 mg intramuscular or intravenous dose delivers 24-hour analgesic and anti-inflammatory cover by reversibly inhibiting cyclooxygenase-1 and cyclooxygenase-2. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Tenoxicam for Injection at our Gujarat, India facility and supplies it to hospital tenders, post-operative analgesia programmes, rheumatology services, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Oxicam non-steroidal anti-inflammatory drug (NSAID) — Tenoxicam for Injection is the long-acting parenteral NSAID for once-daily 20 mg dosing in post-operative pain, acute rheumatic flares (RA, ankylosing spondylitis, osteoarthritis), acute musculoskeletal trauma and acute gouty arthritis. As a non-narcotic, opioid-sparing analgesic with a 72-hour half-life it gives surgical, orthopaedic and rheumatology teams a single-dose-per-day regimen.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, qualified clear-glass vial lyophilisation lines, dedicated handling for a poorly soluble, oxidation-sensitive NSAID requiring freeze-drying as a sterile two-vial powder-plus-diluent presentation, validated lyophilisation cycles with shelf-mapping and full container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, drug master files and CEP-style documentation for registrations across regulated and emerging markets — including ministry-of-health hospital, post-operative-pain and rheumatology tenders.
End-to-end CDMO services: Contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tender-ready vial-plus-diluent packaging and logistics coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Tenoxicam for Injection Demands a Premium Manufacturer
Tenoxicam for Injection occupies a distinct place in the parenteral analgesic shelf. Unlike short-acting NSAIDs that have to be redosed every six to eight hours, tenoxicam's ~72-hour terminal half-life means a single 20 mg intramuscular or short intravenous bolus provides round-the-clock analgesia and anti-inflammatory cover for 24 hours and beyond. That is why anaesthetists reach for it at the end of an orthopaedic, gynaecological or general-surgical case to set up smooth first-day post-operative analgesia; why rheumatologists use it to break an acute flare of rheumatoid arthritis, ankylosing spondylitis or osteoarthritis in patients who cannot tolerate oral therapy; and why it is widely used in acute gouty arthritis and acute soft-tissue trauma when fast, sustained, non-opioid analgesia is the clinical priority.
That clinical reality places real demands on the manufacturer. Tenoxicam is a yellow, crystalline, poorly water-soluble weak acid that is chemically stable in the solid state but sensitive to moisture, oxidation and light. The only practical way to deliver a stable, ready-to-reconstitute 20 mg parenteral dose is as a sterile freeze-dried (lyophilised) powder in a clear-glass vial, supplied with a matched 2 mL diluent ampoule of water for injection. The lyophilisation cycle — freezing, primary drying under vacuum, secondary drying to a tightly controlled residual moisture — is a process discipline in its own right, and any drift translates directly into a cake that fails to reconstitute cleanly. Choosing a Tenoxicam for Injection manufacturer that treats lyophilisation, moisture control, oxidative stability and container-closure integrity as core engineering disciplines is what protects 24-hour post-operative and rheumatology analgesia at the bedside.
What Sets a World-Class Tenoxicam for Injection Manufacturer Apart
A world-class manufacturer of Tenoxicam for Injection invests in three areas that weaker suppliers underfund: a validated lyophilisation cycle that produces an elegant, fast-reconstituting cake with low residual moisture, oxidative- and photo-stability control across the shelf life of both vial and diluent, and tender-ready dossier support for a product that almost always moves through hospital, ministry-of-health and rheumatology procurement. It starts with the active pharmaceutical ingredient — pharmacopoeial-grade tenoxicam sourced from qualified, audited API manufacturers, with full impurity profiling, related-substances control and certificates of analysis cross-checked by the receiving laboratory.
Formulation, freeze-drying and packaging then have to protect the molecule end to end. The bulk solution is built at controlled pH with appropriate bulking and tonicity excipients (typically mannitol and a buffer), sterile-filtered through 0.22 µm membrane, aseptically filled into clear-glass vials under ISO Class 5 air, then lyophilised on validated shelves. Freeze-dry cycle parameters — freezing rate, sublimation pressure, secondary-drying time and end-point moisture (typically <2 %) — are locked into the master batch record. The vial is closed under vacuum with a lyophilisation stopper and crimped with a flip-off aluminium seal; the matched water-for-injection diluent ampoule is filled and terminally sterilised.
Quality Systems Behind Every Tenoxicam for Injection
Every Farbe Firma Tenoxicam for Injection batch is released only after a full stack of quality checks: HPLC assay against USP, BP, IP or EP reference standards, related-substances and degradation-product profiling, reconstitution time and reconstituted-solution appearance, pH and osmolarity of the reconstituted solution, residual moisture by Karl Fischer titration, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, container-closure integrity, and fill-weight verification for the 20 mg lyophilised vial plus the 2 mL diluent ampoule.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, calibrated sterilisation and depyrogenation equipment, validated lyophilisation cycles with shelf and load mapping, calibrated terminal sterilisation cycles for the diluent ampoule, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Stability is tracked under both long-term (30 °C / 65 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions and ICH Q1B photostability requirements.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Tenoxicam for Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables across pain-management, anaesthesia, anti-infective, obstetric, neonatal and supportive-care categories. For Tenoxicam for Injection specifically, we supply 20 mg lyophilised vials with matched 2 mL water-for-injection diluent ampoules under WHO-GMP conditions, with country-specific pack configurations, multi-language artwork and combined vial-plus-ampoule cartons available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the lyophilisation cycle validation report — ready for registration.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination. When a buyer needs Tenoxicam for Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, artwork, freeze-dryer slot and shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and onto the freeze-dryer suite; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing, lyophilisation cycle development, residual-moisture control, reconstitution behaviour, photostability, sterilisation, container-closure and stability choices in real detail. For a drug given to patients in acute post-operative and rheumatology pain, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Tenoxicam for Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Tenoxicam for Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, qualified lyophilisation suites, qualified clear-glass vial filling lines, qualified water-for-injection systems, validated freeze-dry cycles and continuous environmental monitoring.
Which strengths and pack sizes of Tenoxicam for Injection do you supply?
Our standard presentation is 20 mg of lyophilised tenoxicam in a clear-glass vial, supplied with a matched 2 mL water-for-injection diluent ampoule in a combined carton. Custom pack configurations, multi-vial trays and country-specific artwork are available under contract.
Can Farbe Firma support country-specific registrations for Tenoxicam for Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, the lyophilisation cycle validation report, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. Our regulatory team has supported registrations across 30+ countries.
How does Farbe Firma assure the potency and stability of Tenoxicam for Injection?
We lock the lyophilisation cycle to a validated shelf-temperature and pressure profile with end-point residual moisture (typically <2 %) verified by Karl Fischer, run HPLC assay and related-substances testing on every batch, qualify reconstitution time and reconstituted-solution clarity, package in clear-glass vials with matched diluent ampoules in light-protective secondary cartons, and qualify each combined batch against ICH Q1A and ICH Q1B protocols.
What is the minimum order quantity for Tenoxicam for Injection contract manufacturing?
MOQs vary by vial format, label complexity, freeze-dryer load size and dossier requirements. For the 20 mg lyophilised vial plus 2 mL diluent presentation we accommodate hospital-scale and full-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments